Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
02:00am, Wednesday, 03'rd Jan 2024
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overvie
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
02:00am, Tuesday, 02'nd Jan 2024
Strengthens financial flexibility to support the Company's continued growth Strengthens financial flexibility to support the Company's continued growth
3 Stocks That Could Be Monster Winners in 2024
06:50am, Saturday, 30'th Dec 2023
CRISPR Therapeutics' innovative gene-editing therapy could be a game changer. Madrigal Pharmaceuticals hopes to soon win U.S. approval for a potential blockbuster NASH drug.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
11:17am, Friday, 22'nd Dec 2023
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
11:16am, Thursday, 23'rd Nov 2023
The consensus price target hints at a 135.9% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective,
Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment
02:54am, Saturday, 18'th Nov 2023
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Their main candidate drug, ensifentrine, has shown promising resul
Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
02:00am, Friday, 17'th Nov 2023
LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘
Verona Pharma Announces November 2023 Investor Conference Participation
02:00am, Wednesday, 08'th Nov 2023
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overvie
Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect?
11:16am, Tuesday, 07'th Nov 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 119.2% in Verona Pharma PLC American Depositary Share (VRNA). While the effectiveness of this highly sought-aft
Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript
11:58am, Saturday, 04'th Nov 2023
Verona Pharma plc (NASDAQ:VRNA ) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hahn - CFO Dr. Kathy Rickard - Chief Medical Officer
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
02:00am, Thursday, 19'th Oct 2023
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirato
Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround
11:17am, Wednesday, 04'th Oct 2023
Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement amon
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
02:00am, Tuesday, 03'rd Oct 2023
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON an
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
02:00am, Wednesday, 06'th Sep 2023
Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 Substantial reductions in rate and ris
Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon
11:45pm, Monday, 04'th Sep 2023
Verona Pharma has submitted a New Drug Application (NDA) for ensifentrine, a potential treatment for COPD, to the FDA. The FDA has a 60-day window to accept or reject the filing, with a potential appr
